| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Pha...
Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc.
Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIS...
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying build...